Verano Holdings (VRNO) Non Operating Income (2021 - 2026)
Verano Holdings (VRNO) posted quarterly Non Operating Income of -$12.3 million for Q1 2026, down 34.29% year-over-year from -$18.7 million in Q1 2025, and down 29.0% quarter-over-quarter from -$9.5 million in Q4 2025.
Verano Holdings (VRNO) Non Operating Income (2021 - 2026) Analysis & Trends
Verano Holdings (VRNO) has reported Non Operating Income for 6 consecutive years, with -$12.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 34.29% year-over-year to -$12.3 million; the TTM figure through Mar 2026 stood at -$60.7 million (down 21.7% YoY), while the FY2025 annual figure was -$53.6 million, up 2.14% from the prior year.
- Non Operating Income slipped to -$12.3 million in Q1 2026 per VRNO's latest filing, from -$9.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at $3.5 million in Q2 2022 and bottomed at -$24.7 million in Q3 2025.
- Historically, Non Operating Income has averaged -$12.8 million across 5 years, with a median of -$13.9 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 159.19% — and 2023, when it sank 545.66%.
- Verano Holdings' Non Operating Income stood at -$15.3 million in 2022, then climbed by 22.46% to -$11.9 million in 2023, then dropped by 6.18% to -$12.6 million in 2024, then climbed by 24.48% to -$9.5 million in 2025, then decreased by 29.0% to -$12.3 million in 2026.
- Business Quant data shows VRNO's Non Operating Income at -$12.3 million in Q1 2026, -$9.5 million in Q4 2025, and -$24.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | -224.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 5.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 41.90 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 10.70 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Verano Holdings | 442.47 Mn | 357.28 Mn | 99.70 Mn | -13.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.63 Mn |
| Mar 31, 2026 | -12.31 Mn |
| Dec 31, 2025 | -9.54 Mn |
| Sep 30, 2025 | -24.67 Mn |
| Jun 30, 2025 | -14.21 Mn |
| Mar 31, 2025 | -9.17 Mn |
| Dec 31, 2024 | -12.64 Mn |
| Sep 30, 2024 | -13.86 Mn |
| Jun 30, 2024 | -14.24 Mn |
| Mar 31, 2024 | -15.11 Mn |
| Dec 31, 2023 | -11.90 Mn |
| Sep 30, 2023 | -15.17 Mn |
| Jun 30, 2023 | -15.81 Mn |
| Mar 31, 2023 | -15.91 Mn |
| Dec 31, 2022 | -15.35 Mn |
| Sep 30, 2022 | -10.69 Mn |
| Jun 30, 2022 | 3.55 Mn |
| Mar 31, 2022 | -10.67 Mn |
| Dec 31, 2021 | -7.75 Mn |
| Sep 30, 2021 | -8.11 Mn |